Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (0) | Back to Search
MDMX is a novel therapeutic target in cervical carcinoma by inhibiting p53 function
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-A-064-Tuesday
- By: WANG, Hongbo (Yantai, China)
- Co-author(s): Jingwen Zhang: Key Lab of Molecular Pharmacology and Drug Evaluation, Yantai University, Yantai, China
Hongbo Wang: Key Lab of Molecular Pharmacology and Drug Evaluation, Yantai University, Yantai, China;Key Lab of Molecular Pharmacology and Drug Evaluation, Yantai University, Yantai, China
Fenghua Fu: Key lab of Molecular Pharmacology and drug evaluation, Yantai University, Yantai, China - Abstract:
Backgrounds
Cervical cancer is among the most common malignant tumours and the fourth leading cause of cancer death among women worldwide. MDMX, known as a mean to dampen p53 tumor-suppressor function, has recently been found to be overexpressed in certain types of human cancers. However, the role of MDMX in cervical carcinogenesis remains unclear.A..
The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023